What a regulator's shortage notice actually authorises

What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked.

Asking what a regulator's document actually says, since the summaries of it disagree.

I have the primary document open and two secondhand accounts of it that cannot both be right. The primary document is narrower than either.

My question is whether I am reading the scope of it correctly, and what the correct reading rules out as well as what it permits.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

The arithmetic in the opening post is right; the assumption feeding it is the part to check.

Shortage notifications are published by several regulators and are the authoritative source for a question this community usually answers from anecdote.

Answering the question post #2 raises rather than the one it answers.

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

That distinction has done more work for me than anything else in this category.

Post #2 put the caveat in the right place and I want to underline it.

If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category.

Narrowing post #4, because the general version has more than one answer.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

If that is already documented somewhere, ignore me and link it.

Post-authorisation safety commitments are public and are one of the more useful sources for what a regulator considered uncertain at approval.

The strength of my opinion here exceeds the strength of my evidence.

A regulator's public assessment report is usually the single best free source on a compound's evidence base, and it is almost never cited here.

The step people skip is the one I have spelled out.

Post-authorisation safety commitments are public and are one of the more useful sources for what a regulator considered uncertain at approval.

I would not lead a decision with this, but I would not ignore it either.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

Everything in post #9 holds. The case it does not cover is the one I have.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

For what it is worth, the same held on the two occasions I checked.